Background: The primary line of treatment for mild to moderate psoriasis is topical therapy. According to a literature search, there aren’t many studies comparing the effectiveness of topical calcipotriol and betamethasone dipropionate in combination with betamethasone dipropionate alone for treating plaque psoriasis. In this study, the combination of betamethasone and calcipotriol for plaque psoriasis was assessed for safety and efficacy. Methods: The study was conducted over the duration of a year, from January 2023 to December 2023, among inpatients and outpatients who presented to the dermatology department of the Jawaharlal Nehru Medical Col-lege and Hospital in Bhagalpur, Bihar. 66 individuals having a clinical diagnosis of plaque psoriasis were en-listed. A combination of topical calcipotriol 0.005% and betamethasone dipropionate 0.05% was administered once daily to 32 patients, while betamethasone dipropionate 0.05% was applied twice daily to 34 patients. Pso-riasis area and severity index (PASI) was used for clinical follow-up of patients at baseline, week 2, 4, 6, 8, 10, and 12. Patients underwent clinical examinations at each follow-up visit, and the associated PASI values were recorded. They were evaluated for any negative effects as well. Results: Thirty patients in each group completed the study by the conclusion of the twelve-week period. The PASI scores considerably dropped from the baseline in both groups. When compared to betamethasone dipropi-onate 0.05% monotherapy, the combination of calcipotriol 0.005% with betamethasone dipropionate 0.05% resulted in a statistically significant improvement in both clinical response and PASI score reduction. Conclusion: In patients with mild to moderate plaque psoriasis, the combination of calcitriol and betame-thasone proved to be more effective and well-tolerated than betamethasone dipropionate monotherapy.

Background: The primary line of treatment for mild to moderate psoriasis is topical therapy. According to a literature search, there aren’t many studies comparing the effectiveness of topical calcipotriol and betamethasone dipropionate in combination with betamethasone dipropionate alone for treating plaque psoriasis. In this study, the combination of betamethasone and calcipotriol for plaque psoriasis was assessed for safety and efficacy. Methods: The study was conducted over the duration of a year, from January 2023 to December 2023, among inpatients and outpatients who presented to the dermatology department of the Jawaharlal Nehru Medical Col-lege and Hospital in Bhagalpur, Bihar. 66 individuals having a clinical diagnosis of plaque psoriasis were en-listed. A combination of topical calcipotriol 0.005% and betamethasone dipropionate 0.05% was administered once daily to 32 patients, while betamethasone dipropionate 0.05% was applied twice daily to 34 patients. Pso-riasis area and severity index (PASI) was used for clinical follow-up of patients at baseline, week 2, 4, 6, 8, 10, and 12. Patients underwent clinical examinations at each follow-up visit, and the associated PASI values were recorded. They were evaluated for any negative effects as well. Results: Thirty patients in each group completed the study by the conclusion of the twelve-week period. The PASI scores considerably dropped from the baseline in both groups. When compared to betamethasone dipropi-onate 0.05% monotherapy, the combination of calcipotriol 0.005% with betamethasone dipropionate 0.05% resulted in a statistically significant improvement in both clinical response and PASI score reduction. Conclusion: In patients with mild to moderate plaque psoriasis, the combination of calcitriol and betame-thasone proved to be more effective and well-tolerated than betamethasone dipropionate monotherapy.